Extramural Discovery Science Accelerator Award supports cancer researchers with experiments to validate and de-risk existing technologies, advancing ongoing research toward commercialization.
Funder: American Cancer Society
Due Dates: December 1, 2026 (December review) | June 1, 2027 (July review)
Funding Amounts: Up to $75,000 total costs for one year; indirect costs are not allowed
Summary: Supports experiments that validate and de-risk existing cancer research technologies for commercialization.
Key Information: Applicants must be independent investigators at eligible US nonprofit institutions with a plan to license their technology.
The American Cancer Society’s Extramural Discovery Science (EDS) Accelerator Award supports commercialization of ongoing cancer research by funding key experiments to validate and de-risk technologies. It targets work that does not easily fit traditional funding mechanisms, rather than new projects or new directions within existing projects. Proposals must be commercially driven, with a plan to license successful technology to an established company or a start-up.
Supported work may include dosing, toxicity or efficacy testing; testing biopsies or other patient samples to correlate clinical outcomes; and healthcare delivery technologies. Awardees join an entrepreneurial collaborative learning community focused on technology commercialization, with access to educational programming developed by the ACS BrightEdge team and to the team itself.